Predict neurotoxicity risk with higher confidence ahead of in vivo studies. CNS-3D Brain Organoids achieve 83% sensitivity and 89% specificity in predicting clinical seizure liability for small molecules, and 92% sensitivity and 92% specificity for ASOs.

By measuring functional disruption of neuronal network activity, CNS-3D enables confident identification of neurotoxic liabilities while minimizing false positives, outperforming both animal models and 2D co-cultures.

Prioritize AAV vectors earlier using functional, human data. CNS-3D Brain Organoids integrate assessment of transduction efficiency, toxicity, and functional impact in a single model. This approach resolves serotype- and promoter-dependent differences in vector performance and detects disruption of neuronal network activity before overt viability loss

Investigate mechanisms of neurological disease and assess drug efficacy with human biology. CNS-3D Brain Organoids support flexible disease modeling approaches, including patient-derived, CRISPR-engineered, and induced models across a range of diseases, including Rett syndrome, CDKL5 deficiency disorder (CDD), and demyelinating disease. High-throughput functional screening enables identification of compounds that restore neural function without toxicity, supporting rapid prioritization of therapeutic candidates.

Evaluate therapeutic efficacy in demyelinating diseases such as multiple sclerosis with the only 3D cell model that incorporates cortical neurons, astrocytes, and oligodendrocytes. CNS-3D Myelinated Organoids enable quantification of myelin loss, natural recovery, and therapeutic remyelination for human-relevant evaluation of remyelinating therapies and demyelination risk.